CD274 and breast carcinoma: Indeed, for TNBC tumors with high expression of PD-L1, objective responses do not reach 60% and complete responses are limited to 10%, making necessary to identify markers of efficacy within the PD-L1 population [13] in TNBC and basal breast cancer tumors.